Insmed, Inc. (INSM): Price and Financial Metrics

Insmed, Inc. (INSM): $27.96

0.39 (+1.41%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add INSM to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#169 of 347

in industry

INSM Price/Volume Stats

Current price $27.96 52-week high $28.32
Prev. close $27.57 52-week low $16.04
Day low $27.45 Volume 1,881,900
Day high $28.20 Avg. volume 1,254,755
50-day MA $24.94 Dividend yield N/A
200-day MA $21.57 Market Cap 4.00B

INSM Stock Price Chart Interactive Chart >

INSM POWR Grades

  • INSM scores best on the Value dimension, with a Value rank ahead of 60.28% of US stocks.
  • INSM's strongest trending metric is Quality; it's been moving down over the last 177 days.
  • INSM ranks lowest in Momentum; there it ranks in the 4th percentile.

INSM Stock Summary

  • INSMED INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 5.45% of US listed stocks.
  • With a price/sales ratio of 13.51, INSMED INC has a higher such ratio than 92.18% of stocks in our set.
  • INSM's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 1.73% of US stocks.
  • If you're looking for stocks that are quantitatively similar to INSMED INC, a group of peers worth examining would be CYTK, FGEN, APLT, NVAX, and CPTN.
  • INSM's SEC filings can be seen here. And to visit INSMED INC's official web site, go to www.insmed.com.

INSM Valuation Summary

  • In comparison to the median Healthcare stock, INSM's price/earnings ratio is 118.46% lower, now standing at -4.9.
  • Over the past 243 months, INSM's price/sales ratio has gone down 737.2.

Below are key valuation metrics over time for INSM.

Stock Date P/S P/B P/E EV/EBIT
INSM 2023-11-20 12.5 -12.2 -4.9 -6.8
INSM 2023-11-17 12.6 -12.3 -4.9 -6.8
INSM 2023-11-16 12.5 -12.1 -4.8 -6.8
INSM 2023-11-15 12.7 -12.3 -4.9 -6.9
INSM 2023-11-14 12.5 -12.1 -4.9 -6.8
INSM 2023-11-13 12.2 -11.8 -4.7 -6.6

INSM Growth Metrics

    Its 4 year cash and equivalents growth rate is now at 240.87%.
  • Its 2 year cash and equivalents growth rate is now at 20.23%.
  • Its year over year cash and equivalents growth rate is now at 25.86%.
Over the past 70 months, INSM's revenue has gone up $245,358,000.

The table below shows INSM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 245.358 -400.439 -481.534
2022-09-30 242.182 -381.422 -434.389
2022-06-30 221.209 -367.039 -415.958
2022-03-31 201.354 -340.182 -437.634
2021-12-31 188.461 -363.302 -434.654
2021-09-30 173.752 -345.962 -423.889

INSM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • INSM has a Quality Grade of C, ranking ahead of 31.6% of graded US stocks.
  • INSM's asset turnover comes in at 0.172 -- ranking 207th of 682 Pharmaceutical Products stocks.
  • CYRX, CTLT, and ACOR are the stocks whose asset turnover ratios are most correlated with INSM.

The table below shows INSM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.172 0.760 -0.609
2021-06-30 0.192 0.753 -0.585
2021-03-31 0.209 0.754 -0.551
2020-12-31 0.206 0.757 -0.513
2020-09-30 0.215 0.776 -0.415
2020-06-30 0.214 0.795 -0.422

INSM Price Target

For more insight on analysts targets of INSM, see our INSM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $51.78 Average Broker Recommendation 1.4 (Strong Buy)

Insmed, Inc. (INSM) Company Bio


Insmed Incorporated is a biopharmaceutical company focused on developing targeted inhaled therapies for patients suffering from rare lung diseases. The company was founded in 1999 and is based in Bridgewater, New Jersey.


INSM Latest News Stream


Event/Time News Detail
Loading, please wait...

INSM Latest Social Stream


Loading social stream, please wait...

View Full INSM Social Stream

Latest INSM News From Around the Web

Below are the latest news stories about INSMED INC that investors may wish to consider to help them evaluate INSM as an investment opportunity.

Insmed To Present at the Nasdaq 49th Investor Conference

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the Nasdaq 49th Investor Conference in London on Wednesday, December 6, 2023, at 8:30 a.m. ET/1:30 p.m. GMT.

Yahoo | November 29, 2023

Vanguard Group Inc Adds Shares in Insmed Inc

Vanguard Group Inc, a prominent investment firm, has recently expanded its portfolio by acquiring additional shares in Insmed Inc (NASDAQ:INSM). On October 31, 2023, Vanguard Group Inc reported an addition of 1,089,800 shares in Insmed Inc, reflecting an 8.18% change in their holdings. The transaction was executed at a price of $25.06 per share, increasing Vanguard's total share count in Insmed to 14,410,356.

Yahoo | November 14, 2023

Insmed To Present at Two November Conferences

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences:

Yahoo | November 8, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 21 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

Yahoo | November 3, 2023

Insmed Holds Second Annual Global Day of Good to Benefit Communities Across the Globe

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today holds its second annual Global Day of Good, with hundreds of Insmed employees volunteering simultaneously in their respective communities.

Yahoo | November 2, 2023

Read More 'INSM' Stories Here

INSM Price Returns

1-mo 17.73%
3-mo 6.47%
6-mo 41.21%
1-year 50.08%
3-year -28.95%
5-year 77.41%
YTD 39.94%
2022 -26.65%
2021 -18.17%
2020 39.41%
2019 82.01%
2018 -57.92%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!